

PAPER

View Article Online
View Journal | View Issue

Cite this: *Nanoscale Adv.*, 2023, 5, 5520

Near infrared conjugated polymer nanoparticles (CPNTM) for tracking cells using fluorescence and optoacoustic imaging†

Ana Muñoz-García,^{†ab} Alejandra Hernandez Pichardo,^{‡ac} James Littlewood,^{cd} Suzannah Tasker,^a Jack Sharkey,^e Bettina Wilm,^{ac} Hannah Peace,^{†f} Dermott O'Callaghan,^f Mark Green,^f Arthur Taylor^{*ac} and Patricia Murray^{†ac}

Tracking the biodistribution of cell therapies is crucial for understanding their safety and efficacy. Optical imaging techniques are particularly useful for tracking cells due to their clinical translatability and potential for intra-operative use to validate cell delivery. However, there is a lack of appropriate optical probes for cell tracking. The only FDA-approved material for clinical use is indocyanine green (ICG). ICG can be used for both fluorescence and photoacoustic imaging, but is prone to photodegradation, and at higher concentrations, undergoes quenching and can adversely affect cell health. We have developed novel near-infrared imaging probes comprising conjugated polymer nanoparticles (CPNsTM) that can be fine-tuned to absorb and emit light at specific wavelengths. To compare the performance of the CPNsTM with ICG for *in vivo* cell tracking, labelled mesenchymal stromal cells (MSCs) were injected subcutaneously in mice and detected using fluorescence imaging (FI) and a form of photoacoustic imaging called multispectral optoacoustic tomography (MSOT). MSCs labelled with either ICG or CPNTM 770 could be detected with FI, but only CPNTM 770-labelled MSCs could be detected with MSOT. These results show that CPNsTM show great promise for tracking cells *in vivo* using optical imaging techniques, and for some applications, out-perform ICG.

Received 22nd July 2023
Accepted 10th September 2023

DOI: 10.1039/d3na00546a

rsc.li/nanoscale-advances

Introduction

Cell therapies have potential for treating various conditions, including cancer,¹ degenerative diseases² and acute tissue injury.³ One of the barriers facing the development and optimisation of these therapies is that it can be difficult to track the cells *in vivo* following their administration. Without knowing the bio-distribution and fate of the cells, their safety and efficacy cannot be adequately assessed. Tracking cells *in vivo* can also shed light on their mechanisms of action. For instance, using bioluminescence imaging (BLI) to assess the biodistribution of kidney-derived regenerative cells and mesenchymal stromal cells (MSCs), we previously found that following intravenous (IV) administration in

mice, the cells were entrapped in the lungs and did not persist beyond 24 hours.^{4–6} This showed that the therapeutic effects of the cells were not due to them homing to target organs such as the kidney and replacing injured host cells as previously thought,^{7,8} but were instead due to paracrine or endocrine effects.⁹

Imaging cells *in vivo* with BLI requires that the administered cells express a luciferase enzyme, the most common being firefly luciferase (Fluc). In the presence of oxygen, ATP, Mg²⁺ and the substrate luciferin, Fluc catalyses the production of light. BLI is a very effective technique for tracking cell fate because in addition to indicating the location of the cells, it also shows if they are alive or not; this is because light is only emitted from Fluc-expressing (Fluc⁺) cells if they are viable.⁴ However, problems with BLI include poor spatial resolution (2–5 mm) and low penetration depth (~1 cm).¹⁰ Moreover, the requirement for a substrate to be administered means BLI is not suitable for clinical imaging.

Some of these problems can be overcome by using cell tracking nanoprobe that can rapidly label the majority of cells within a population and enable them to be imaged using a clinically translatable imaging modality such as fluorescence imaging (FI) or multispectral optoacoustic tomography (MSOT).¹¹ MSOT is an emerging technology that is well-established for small animal imaging, and its effectiveness as a diagnostic tool in human patients is being assessed in

^aDepartment of Molecular Physiology and Cell Signalling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. E-mail: p. a.murray@liverpool.ac.uk

^bCentre for Genomics and Child Health, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK

^cCentre for Pre-clinical Imaging, University of Liverpool, Liverpool, UK

^diThera Medical GmbH, Munich, Germany

^ePerkin Elmer, UK

^fStream Bio, Alderley Park, UK

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3na00546a>

‡ Equal contribution.



a variety of clinical trials.¹² MSOT is a type of photoacoustic imaging that involves illuminating a subject with near infrared (NIR) laser light, whereby photoabsorbers present within the tissue absorb the light and undergo thermoelastic expansion, generating acoustic waves that can be detected at the body surface. Whereas BLI and FI have poor spatial resolution (2–5 mm) and relatively low penetration depth (1–2 cm), MSOT has the advantage of higher spatial resolution (~150 μ m) and greater penetration depth (4–5 cm).¹⁰ Moreover, in contrast to BLI and FI which are typically used to generate planar images, MSOT produces a tomographic image, allowing the position of cells to be identified in 3D.

Near infrared (NIR) nanoprobe that absorb and emit light in the “optical window” (650–900 nm) are particularly suited for tracking cells with both FI and MSOT *in vivo*¹³ because within these wavelengths, there is limited absorbance by haemoglobin. Indocyanine green (ICG) is an NIR dye that has been used successfully as a contrast agent in both FI and MSOT applications in small animals,^{14–16} and is FDA-approved for various clinical applications, including the assessment of liver function and the identification of tumour margins during surgery.^{17,18} ICG has also been used to label cells and track them *in vivo* in mice using FI and MSOT.¹⁵ However, one of the disadvantages of ICG is that it undergoes a degree of photodegradation,¹⁹ which affects signal intensity, and also has a tendency to leach out of the labelled cells,¹⁵ potentially labelling surrounding cells and tissues and leading to false positive results.

To overcome the problems with ICG, we developed a novel type of NIR nanoparticle called “conjugated polymer nanoparticles” (CPNsTM)^{20,21} and assessed their potential for cell tracking. CPNsTM are next generation organic imaging agents, which exhibit exceptional emission brightness and stability whilst avoiding the use of heavy metals sometimes found in other nanoparticle systems.²² The particles used in the study are approximately 60–70 nm in diameter, with a carboxylate rich surface and contain magnetic iron oxide particles. The embedded iron oxide particles offer a further imaging modality if required (*i.e.*, magnetic resonance imaging) and further provide the benefit of magnetic materials, such as ease of manipulation and purification *via* magnetic separation. The fluorescence quantum yields of the materials are estimated to be *ca.* 1–2%,²² yet brightness should be significantly higher relative to other nanomaterials with similar fluorescence quantum yields due to their large extinction coefficient.²³

Here, we have assessed the potential of a range of NIR CPNTM probes (CPNTM 770, CPNTM 820, CPNTM 830, CPNTM 840, CPNTM 1000) for labelling human umbilical cord tissue-derived MSCs (hUC-MSCs). We imaged them *in vitro* with NIR fluorescence microscopy, and have compared the performance of CPNTM 770 nanoprobe with ICG for cell tracking in mice using FI and MSOT. We found that all NIR CPNsTM could be used to detect labelled hUC-MSCs with confocal microscopy without any noticeable effect on cell viability. *In vitro* analysis showed that CPNTM 770 probes displayed the highest radiant efficiency as well as the most intense signal with MSOT, indicating that these probes would likely be the most effective for tracking cells *in vivo*. Using flow cytometry, we compared the labelling efficiency

of different concentrations of CPNTM 770 nanoprobe in comparison with ICG. With both ICG and CPNTM 770 (irrespective of the concentration used), the majority of hUC-MSCs within the population were labelled. To confirm that the cells remained viable *in vivo*, Fluc⁺ hUC-MSCs were labelled with either CPNTM 770 nanoprobe or ICG, and following subcutaneous injection into mice, were imaged with BLI. FI showed that the performance of CPNTM 770 and ICG was similar, with both tracking agents allowing the cells to be easily detected. However, with MSOT, ICG-labelled hUC-MSCs were barely detectable, whereas those labelled with CPNTM 770 were easily visible. The CPNTM 770 nanoprobe therefore has some advantages over ICG and shows great promise for future cell tracking applications with both FI and MSOT.

Experimental

Materials

Unless otherwise indicated, general reagents and cell culture reagents were purchased from Sigma-Aldrich. The following conjugated polymer nanoparticles with a carboxylate functionalised surface were supplied by Stream Bio as an aqueous suspension: CPNTM 770, CPNTM 820, CPNTM 830, CPNTM 840, CPNTM 1000. The nanoparticles are 70–80 nm in size, according to measurements obtained using dynamic light scattering (DLS). The excitation and emission maxima for each of the particles is as follows: CPNTM 770 (excitation 610 nm, emission 770 nm); CPNTM 820 (excitation 640 nm, emission 820 nm); CPNTM 830 (excitation 610 nm, emission 830 nm); CPNTM 840 (excitation 630 nm, emission 840 nm); CPNTM 1000 (excitation 750 nm, emission 1000 nm) (see ESI Fig. S1†). The particles were used as received without further purification (batch numbers CPN770 – 20062977021115; CPN820 – 20090382021115; CPN830 – 21070883021019; CPN840 – 20081384021115; CPN1000 – 200714100021115).²⁰

Cell culture

hUC-MSCs were obtained from NHS Blood and Transplant (NHSBT, UK) after passage 2. hUC-MSCs expressing the luc2 firefly luciferase (FLuc) reporter (FLuc⁺ hUCMSCs) were used for *in vivo* experiments as a tracking control. To generate FLuc-expressing cells, lentiviral transduction was undertaken using a vector encoding the FLuc reporter and ZsGreen under the control of the constitutive elongation factor 1- α (EF1 α). The pHIV-Luc-ZsGreen vector was kindly gifted by Bryan Welm and Zena Werb (Addgene plasmid #39196).²⁴ Both unmodified hUC-MSCs and FLuc⁺ hUC-MSCs were expanded in minimum essential medium α (MEM α) containing GlutaMAX (32561-029, Gibco) supplemented with 10% fetal bovine serum (FBS; 10270-106, Gibco) in the presence of 1% penicillin–streptomycin, and maintained in a regular humidified air incubator (approx. 90–95% humidity) set at 5% CO₂ and 37 °C.

Cell labelling

hUC-MSCs or FLuc⁺ hUC-MSCs were labelled with a range of near infra-red (NIR) CPNTM probes (CPNTM 770, CPNTM 820,



CPNTM 830, CPNTM 840, or CPNTM 1000; Stream Bio, UK). All probes were used from a stock concentration of 1×10^9 probes per ml, diluted in fresh culture media (MEM α with 10% FBS, 1% penicillin-streptomycin) to a concentration of 1×10^8 particles per ml (or as otherwise indicated), and incubated with sub-confluent cells for 24 h. This meant that the labelling medium comprised 90% cell culture medium and 10% nanoparticle suspension. In parallel, cells were also labelled with $100 \mu\text{g ml}^{-1}$ ICG (27462, Cayman Chemical, 10 mg ml^{-1} in DMSO) for comparison. ICG cell staining consisted of a 30 min incubation in culture media as previously described,¹⁴ followed by two consecutive washes with fresh medium to remove any traces of ICG in suspension. Following staining, cells were kept in regular culture medium for approximately 24 h prior to any *in vitro* analysis and/or *in vivo* administration.

Cells labelled with NIR-CPNTM nanoprobe or ICG were either fixed for microscopy imaging (see below), plated in a 96-well plate for assessment of cell viability (see below), or suspended in phosphate buffered saline (PBS) for flow cytometry (see below) and/or animal experiments. To obtain a suspension of hUC-MSCs, cells were incubated with 0.25% Trypsin-EDTA for a maximum of 5 min. Cells were counted using a TC20 Automated Cell Counter (BioRad), centrifuged at $400 \times g$ for 3 min, and suspended to the density required for each specific downstream analysis.

Immunofluorescence microscopy

hUC-MSCs were seeded into chamber slides at a density of 1×10^4 cells per well. Following labelling with CPNTM nanoprobe or ICG, cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min and mounted using FluoroshieldTM with DAPI (F6057, Sigma). To capture images, an Andor Dragonfly spinning disk microscope system coupled to an EMCCD camera was used with a $40 \times / 1.3$ oil objective. Images were captured using the 637 or 750 nm laser lines. The emission filters used were 600/50 or 700/75. Image visualization was done using the IMARIS version 9.9.0 (Bitplane, Schlieren, Switzerland) software package.

Cell viability

5×10^3 hUC-MSCs were seeded into 96-well plates (Corning) in $100 \mu\text{l}$ of medium and allowed to attach for 24 h. The viability of hUC-MSCs after 24 h exposure to CPNTM nanoprobe (at a concentration of 1×10^8 particles per ml) was then determined by the CellTiter-GloTM Luminescent Cell Viability Assay (Promega Corporation). Tests were performed in triplicate (with 3 technical replicates for each biological replicate). Two PBS wash steps were undertaken between CPNTM exposure and performing the assay. Luminescence was measured in a multi-well plate reader (FLUOstar Omega, BMG Labtech).

Flow cytometry

Prior to undertaking flow cytometry analysis, hUC-MSCs were seeded into a 12-well plate at a density of 25×10^3 cells per well in $800 \mu\text{l}$ medium. After labelling with CPNTM probes or ICG (see above), cells were transferred to flow cytometry tubes with

strained caps ($35 \mu\text{m}$ mesh; CorningTM, FisherScientific) and 10 000 events were analysed per sample. Data were acquired on a BD CANTO II flow cytometer using BD FACSDiva software (BD Biosciences) using a 633 nm excitation laser and a 780/60 emission filter. Data analyses were performed using the FCSalyzer 0.9.22 software.

Animal experiments

Three male eight to ten-week-old C57BL/6 albino mice were used for all animal experiments. Mice were housed in individually ventilated cages (IVCs) under a 12 h light/dark cycle and provided with standard food and water *ad libitum*. All animal procedures were performed under a license granted by the Home Office under the Animals (Scientific Procedures) Act 1986²⁵ and were approved by the University of Liverpool Animal Welfare and Ethics Review Board. Prior to cell administration, fur was removed with clippers and depilatory cream (Veet Hair Removal Cream 8336076, RB Healthcare, UK). Mice received a total of 4 subcutaneous (SC) injections: 5×10^5 FLuc⁺ hUC-MSCs labelled with CPNTM probes into the bottom right flank; 5×10^5 unlabelled FLuc⁺ hUCMSCs into the bottom left flank; $100 \mu\text{l}$ of CPNTM probes stock solution into the top left flank; and 5×10^5 FLuc⁺ hUC-MSCs labelled with ICG in the top right flank (Fig. 3A). Animals were imaged shortly after injection and the whole experiment was performed under terminal anaesthesia with isoflurane.

Fluorescence imaging (FI)

For *in vitro* FI, for each probe, $50 \mu\text{l}$ of the stock solution (concentration of $100 \mu\text{g ml}^{-1}$ for both CPNs and ICG) was added to a well of a black 96-well plate for measurement. Filter sets (excitation/emission wavelength, in nm) were optimised for each probe as follows: CPN770 (605/820), CPN820 (639/840), CPN840 (605/840), CPN1000 (745/840*), ICG (745/820). *In vivo* FI studies were performed before BLI. The mice were imaged using an IVIS imaging system (IVIS[®] Spectrum, PerkinElmer) and detection was performed using a range of excitation (ex)/emission (em) filter combinations for spectral unmixing. These were 605(ex): 760, 780, 800, 820, 840(em); 710(ex):780, 800, 820, 840(em); 745(ex):820, 840(em) nm. Acquisition was performed with a 13.3 cm FOV, f-stop of 2 and binning of 8. Spectral unmixing for ICG and CPNTM770 was undertaken with Living Image v. 4.5.2 (PerkinElmer) and images are shown as colour-coded composites of the two probes.

Bioluminescence imaging (BLI)

For *in vivo* BLI, mice received a subcutaneous injection of D-Luciferin (Promega, UK) ($10 \mu\text{L g}^{-1}$ [body weight] of a 47 mM stock solution) after FI. 20 min after administration of the substrate, the animals were imaged with the IVIS system. Data are displayed as radiance (photons/second/centimeter²/steradian), where the signal intensity scale is normalised to the acquisition conditions. Acquisition was performed without an emission filter, a 13.3 cm FOV, f-stop of 1, and a binning of 8.



Multispectral optoacoustic tomography (MSOT)

MSOT was performed using the inVision 256-TF system (iThera Medical, Germany). Images were reconstructed in viewMSOT 4.0.1.34 software (iThera Medical, Germany) using the BP 4.0 pre-set. Reconstruction FOV was set to 25 mm. The isoflurane dose was titrated to produce a respiratory rate of 1 Hz. The mouse was placed in the MSOT mouse holder supine with a thin layer of clear non-absorbing ultrasound gel applied (Barclay-Swann, UK). The holder and mouse were transferred into the inVision 256-TF water bath previously heated to 34 °C. The mouse was allowed to equilibrate to the water bath temperature for 15 minutes before imaging was started. Mice were imaged from neck to hindquarters in 1 mm steps. 10 frames were acquired per stage position and wavelength then averaged. Mice were imaged at 36 wavelengths: from 700 to 875 nm in steps of 5 nm. After image reconstruction, images were spectrally unmixed for haemoglobin, oxyhaemoglobin, ICG, and CPNTM 770 using the linear regression algorithm (viewMSOT, iThera Medical, Germany) and their *a priori* spectra.

Results and discussion

Cellular uptake of NIR CPNsTM

To investigate if the NIR CPNsTM were taken up by hUC-MSCs, the cells were incubated with each type of CPNTM at a concentration of 1×10^8 particles per ml for 24 h, or with ICG at a concentration of $100 \mu\text{g ml}^{-1}$ for 30 min as previously

described.¹⁴ This concentration of ICG was used because a previous report has shown that higher concentrations lead to a statistically significant reduction in human MSC viability.¹⁴ Following fixation, the cells were imaged using confocal microscopy. The CPNsTM were readily taken up by the hUC-




Fig. 2 Effect of CPNTM nanoprobes on hUC-MSC viability. Cells were exposed to CPNTM nanoprobes at a concentration of 1×10^8 particles per ml for 24 h. Viability was assessed using CellTiter-GloTM that generates luminescence based on ATP levels. The viability of the cells was not statistically significantly different from controls, irrespective of the type of CPNTM nanoprobe that was used. $n = 3$.




Fig. 1 *In vitro* labelling of hUC-MSCs with NIR CPNTM nanoprobes (1×10^8 particles per ml) and ICG ($100 \mu\text{g ml}^{-1}$). Cells were fixed 24 h following labelling and imaged by confocal microscopy. Scale bar, 30 μm .



MSCs, with the majority of cells within the population becoming labelled (Fig. 1). The signal intensity of the cells labelled with the CPNTM 1000 nanoparticles appeared lower than that of the cells labelled with the other CPNTM probes and ICG. This was likely because the lasers and fluorescence filters available on the confocal microscope were not optimal for detecting these nanoparticles. The perinuclear staining pattern of the CPNTM probes is consistent with their accumulation in the endolysosomal compartment, which is typical for most cell labelling nanoparticles, including quantum dots²⁶ and iron oxide nanoparticles,²⁷ as well as CPNs.²⁸ This was also the case for ICG, which is mainly taken up into cells *via* endocytosis.^{29,30} The difference in staining pattern between the CPNTM probes and ICG likely reflects the fact that in addition to becoming localised to lysosomes, the ICG is also detected in the mitochondria and Golgi.^{29,30} At the concentration used, none of the CPNTM probes had any significant effect on hUC-MSC viability (Fig. 2).

Flow cytometric analysis of hUC-MSCs labelled with CPNTM 770 nanoprobe or ICG

Prior to undertaking flow cytometry, we first assessed the radiant efficiency and photoacoustic signal intensity of the CPNTM nanoprobe *in vitro* using FI (IVIS Spectrum) and MSOT, respectively. Because the CPNTM 770 nanoprobe had the highest radiant efficiency and also the strongest signal with MSOT (ESI Fig. S2†), subsequent experiments were performed exclusively with this CPNTM nanoprobe. Flow cytometric analyses of the CPNTM 770 labelled hUC-MSCs was then undertaken to confirm that the majority of cells were labelled, and to determine the relationship between labelling concentration and fluorescence intensity. hUC-MSCs were labelled for 24 h with the following dilutions of a stock concentration of 1×10^9 CPNTM 770 nanoprobe per ml: 1 : 10, 1 : 20, 1 : 50, 1 : 100 and 1 : 200. Unlabelled hUC-MSCs served as a negative control, and ICG-labelled cells as the positive control. Even with the lowest concentration of CPNTM 770 nanoprobe, the majority of hUC-MSCs showed a noticeable




Fig. 3 Flow cytometry of hUC-MSCs labelled with a concentration range of CPNTM 770 nanoprobe. (A) Histograms of unlabelled cells (negative control), cells labelled with $100 \mu\text{g ml}^{-1}$ ICG (positive control) or a 1 : 10, 1 : 20, 1 : 50, 1 : 100, 1 : 200 dilution of a stock concentration of 1×10^9 CPNTM 770 nanoprobe per ml. (B) Mean fluorescence intensity (MFI) of the different probes in arbitrary units (A.U.).



increase in fluorescence compared to unlabelled controls, and the mean fluorescence intensity increased with increasing concentrations of nanoprobe; this was likely due to an increase in the number of nanoprobe per cell. The majority of ICG-labelled hUC-MSCs also showed a noticeable increase in fluorescence compared to unlabelled cells (Fig. 3). The concentration of ICG used to label the hUC-MSCs was $100 \mu\text{g ml}^{-1}$ over 30 min. Increasing the concentration of ICG would be unlikely to increase the signal intensity because at concentrations above $80 \mu\text{g ml}^{-1}$, quenching starts to occur,³¹ and over $100 \mu\text{g ml}^{-1}$, fluorescence intensity decreases sharply.³¹ This is because at higher concentrations, there is an increase in the ratio of ICG polymers

compared to monomers, the former having a weaker yield of fluorescence.³¹ Moreover, higher concentrations would be expected to reduce the viability of the cells, as has previously been shown.¹⁴ In light of these earlier studies, the highest labelling concentration of ICG used here was $100 \mu\text{g ml}^{-1}$.

Fluorescence, MSOT and bioluminescence imaging of UC-MSCs labelled with CPNTM 770- or ICG following subcutaneous injection in mice

To compare the effectiveness of CPNTM 770 nanoprobe and ICG for tracking cells *in vivo* with FI and MSOT, hUC-MSCs were




Fig. 4 Multimodal *in vivo* imaging of Fluc⁺ hUC-MSCs labelled with CPNTM 770 nanoprobe or ICG following subcutaneous injection. (A) Schematic showing the sites of subcutaneous injection of the Fluc⁺ hUC-MSCs or neat CPNTM 770 nanoprobe. Fluc⁺ hUC-MSCs were labelled with 1×10^8 CPNTM 770 nanoprobe per ml for 24 h, or with $100 \mu\text{g ml}^{-1}$ ICG for 30 min. 0.5×10^6 cells were injected in $100 \mu\text{l}$ of saline, and neat CPNTM 770 nanoprobe was injected at a concentration of 1×10^8 particles in $100 \mu\text{l}$. (B) Representative fluorescence image of injected mouse shortly after cell administration, after spectral unmixing. Unlabelled Fluc⁺ hUC-MSCs served as a negative control. (C) MSOT image of the same mouse; left image shows *x-z* plane and right image shows tomographic reconstruction, with two different colour scales for each probe. (D) Bioluminescence image of the same mouse shown in (B) and (C). $n = 3$.



labelled with 1×10^8 particles per ml (equivalent to 1:10 dilution of the stock) for 24 h, or with $100 \mu\text{g ml}^{-1}$ ICG for 30 min hUC-MSCs expressing firefly luciferase (Fluc) were used for these experiments to establish if the labelled cells remained viable *in vivo*. Unlabelled Fluc⁺ hUC-MSCs and Fluc⁺ hUC-MSCs labelled with CPNTM 770 nanoprobe or ICG were injected into the dorsal flanks of mice at a concentration of 5×10^5 cells in an injection volume of 100 μl . Neat CPNTM 770 nanoprobe was also injected at a concentration of 1×10^8 particles in 100 μl to serve as a positive control (Fig. 4A). Mice were imaged shortly after administration using an IVIS Spectrum. Cells labelled with CPNTM 770 or ICG and the neat CPNTM 770 nanoprobe were readily visible and distinguishable after spectral unmixing (Fig. 4B). As expected, unlabelled control cells did not emit a detectable signal.

While under anaesthesia, the mice were imaged with MSOT and the signal was spectrally unmixed using the relevant spectra (ESI Fig. S3†). Interestingly, although the signal intensity of the CPNTM 770- and ICG-labelled hUC-MSCs appeared similar with FI (Fig. 3B), with MSOT, the signal from the CPNTM 770- labelled cells and neat CPNTM 770 nanoprobe was noticeably stronger than from the ICG-labelled cells. In fact the ICG-labelled cells were not only barely visible, but also of the same intensity as other background signals seen at this wavelength (Fig. 4C and S4†). Prior to MSOT imaging, the mice were administered with luciferin to enable BLI to be performed immediately following MSOT while the mice were still anaesthetised. As expected, the unlabelled and labelled hUC-MSCs showed a detectable signal, indicating that the cells were viable, whereas no signal was detected from the neat CPNTM 770 nanoprobe (Fig. 4D).

When ICG is administered intravenously, it is mainly in the monomeric form and can be readily visualised in the vasculature using MSOT, a common application being the assessment of liver function.³² The reason why ICG-labelled hUC-MSCs gave only a weak signal in the current study is possibly because following endocytosis, the ICG becomes concentrated in the endolysosomal compartment, likely favouring an increase in the polymeric form of ICG that is known to have less favourable optical properties.³¹ This article has focussed on comparing the performance of the CPNTM 770 with ICG because the latter is FDA-approved. However, it should be noted that other photoacoustic contrast agents, such as carbon nanotubes and gold nanorods have also been used to track cells *in vivo* with photoacoustic imaging.¹⁰ However, a drawback with these agents is that they are not fluorescent, which means they are not useful for tracking cells *in vitro* or *in vivo* using fluorescence imaging. Moreover, carbon nanotubes and gold nanorods can be toxic to cells and tissues, especially when used at high concentrations.^{33,34} We have previously shown that the fluorescent properties of the CPNTM nanoprobe compares well to other fluorescent nanoprobe, such as quantum dots. For instance, the CPNTM nanoprobe show limited phototoxicity, are photostable, and show good resistance to photobleaching.²² Moreover, not only does the fluorescence intensity of the CPNTM nanoprobe decrease by only 25% following 2 hours of continuous irradiation, but the photobleaching is reversible, with fluorescence intensity being able to recover to its original level.²²

Although the CPNTM 770 nanoprobe proved more effective than ICG for tracking cells with MSOT, the performance of the two contrast agents was comparable when used for tracking cells with FI. A possible explanation for this might be the larger number of photoactive units and larger absorption cross section in a conjugated polymer nanoparticle when compared to a single molecule imaging agent. This can result in a greater proportion of the absorbed light being converted to heat and ultrasound waves rather than being emitted as light, thereby generating a stronger signal in MSOT.³⁵ Taken together, the results show that CPNTM 770 nanoprobe and ICG can both be used to track cells *in vivo* using FI, but the CPNTM 770 nanoprobe are far superior for tracking cells with MSOT.

Conclusions

Here we assessed the potential of NIR CPNTM nanoprobe as cell tracking agents in comparison to the FDA-approved NIR dye, ICG. We found that similarly to ICG, nanoprobe with emission maxima ranging from 770 nm to 1000 nm were readily uptaken by hUC-MSCs, enabling the cells to be imaged *in vitro* using confocal microscopy. Following subcutaneous administration into mice, CPN 770TM - labelled hUC-MSCs and ICG-labelled hUC-MSCs could both be readily detected *in vivo* using FI. However, using MSOT, in contrast to CPN 770TM - labelled cells which were easily visible, ICG-labelled cells could barely be detected. NIR CPNTM nanoprobe, and CPN 770TM in particular, have great potential for cell tracking applications *in vivo* using FI and MSOT. The presence of iron oxide nanoparticles within the core of the nanoprobe also means that they could be useful for magnetic resonance imaging and magnetic particle imaging. Another advantage of CPN 770TM over ICG is that with the former, it is possible for the labelled cells to be analysed using microscopy following animal sacrifice. This would be difficult with ICG-labelled cells due to the rapid photo-degradation of ICG.

Author contributions

Ana Muñiz-García: methodology, data collection and analysis, writing – original draft, writing – review and editing. Alejandra H Pichardo: methodology, data collection and analysis, writing – original draft, writing – review and editing. James Littlewood: methodology, data collection and analysis, writing – original draft, writing – review and editing. Suzannah Tasker: methodology, data collection and analysis, writing – review and editing. Jack Sharkey: methodology, data collection and analysis, writing – review and editing. Bettina Wilm: writing – review and editing, supervision. Hannah Peace: methodology, writing – review and editing. Dermott O'Callaghan: resources, methodology, writing – review and editing. Mark Green: conceptualization, data analysis, writing – original draft, writing – review and editing. Arthur Taylor: methodology, data collection and analysis, writing – original draft, writing – review and editing, supervision. Patricia Murray: conceptualization, data analysis, writing – original draft, writing – review and editing, supervision, funding acquisition.



Conflicts of interest

JL was employed by iThera Medical; JS is employed by PerkinElmer; HP is employed by Stream Bio and DO'H and MG are shareholders.

Acknowledgements

We gratefully acknowledge the support of the University of Liverpool's Flow Cytometry Facility, Centre for Cell Imaging and Centre for Preclinical Imaging. This work was funded by a Business Interaction Voucher from the UK's Royal Microscopy Society and the Biotechnology and Biological Sciences Research Council awarded to PM and Stream Bio, and by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813839.

References

- 1 R. C. Sterner and R. M. Sterner, CAR-T cell therapy: current limitations and potential strategies, *Blood Cancer J.*, 2021, **11**, 69.
- 2 R. A. Barker, M. Parmar, L. Studer and J. Takahashi, Human trials of stem cell-derived dopamine neurons for Parkinson's disease: dawn of a new era, *Cell Stem Cell*, 2017, **21**(5), 569–573.
- 3 F. Amadeo, K. Trivino Cepeda, J. Littlewood, B. Wilm, A. Taylor and P. Murray, Mesenchymal stromal cells: what have we learned so far about their therapeutic potential and mechanisms of action?, *Emerging Top. Life Sci.*, 2021, **5**(4), 549–562.
- 4 L. Scarfe, A. Taylor, J. Sharkey, R. Harwood, M. Barrow, J. Comenge, L. Beeken, C. Astley, I. Santeramo, C. Hutchinson, L. Ressel, J. Smythe, E. Austin, R. Levy, M. J. Rosseinsky, D. J. Adams, H. Poptani, B. K. Park, P. Murray and B. Wilm, Non-invasive imaging reveals conditions that impact distribution and persistence of cells after *in vivo* administration, *Stem Cell Res. Ther.*, 2018, **9**(1), 332.
- 5 F. Amadeo, A. Plagge, A. Chacko, B. Wilm, V. Hanson, N. J. Liptrott, P. Murray and A. Taylor, Firefly luciferase offers superior performance to AkaLuc for tracking the fate of administered cell therapies, *Eur. J. Nucl. Med. Mol. Imaging*, 2022, **49**, 796–808.
- 6 F. Amadeo, V. Hanson, N. J. Liptrott, B. Wilm, P. Murray and A. Taylor, Fate of intravenously administered umbilical cord mesenchymal stromal cells and interactions with the host's immune system, *Biomed. Pharmacother.*, 2023, **159**, 114191.
- 7 M. Morigi, B. Imberti, C. Zoja, D. Corna, S. Tomasoni, M. Abbate, D. Rottoli, S. Angioletti, A. Benigni, N. Perico, M. Alison and G. Remuzzi, Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure, *J. Am. Soc. Nephrol.*, 2004, **15**(7), 1794–1804.
- 8 E. Ronconi, C. Sagrinati, M. L. Angelotti, E. Lazzeri, B. Mazzinghi, L. Ballerini, E. Parente, F. Becherucci, M. Gacci, M. Carini, E. Maggi, M. Serio, G. B. Vannelli, L. Lasagni, S. Romagnani and P. Romagnani, Regeneration of Glomerular Podocytes by Human Renal Progenitors, *J. Am. Soc. Nephrol.*, 2009, **20**(2), 322–332.
- 9 Y. Geng, L. Zhang, B. Fu, J. Zhang, Q. Hong, J. Hu, D. Li, C. Luo, S. Cui, F. Zhu and X. Chen, Mesenchymal stem cells ameliorate rhabdomyolysis-induced acute kidney injury *via* the activation of M2 macrophages, *Stem Cell Res. Ther.*, 2014, **5**(3), 80.
- 10 L. Scarfe, N. Brilliant, J. D. Kumar, N. Ali, A. Alrumayh, M. Amali, S. Barbellion, V. Jones, M. Niemeijer, S. Potdevin, G. Roussignol, A. Vaganov, I. Barbaric, M. Barrow, N. C. Burton, J. Connell, F. Dazzi, J. Edsbadge, N. S. French, J. Holder, C. Hutchinson, D. R. Jones, T. Kalber, C. Lovatt, M. F. Lythgoe, S. Patel, P. S. Patrick, J. Piner, J. Reinhardt, E. Ricci, J. Sidaway, G. N. Stacey, P. J. Starkey Lewis, G. Sullivan, A. Taylor, B. Wilm, H. Poptani, P. Murray, C. E. P. Goldring and B. K. Park, Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies, *npj Regener. Med.*, 2017, **2**, 28.
- 11 J. Comenge, J. Sharkey, O. Fragueiro, B. Wilm, M. Brust, P. Murray, R. Levy and A. Plagge, Multimodal cell tracking from systemic administration to tumour growth by combining gold nanorods and reporter genes, *eLife*, 2018, **7**, e33140.
- 12 W. M. MacCuaig, M. A. Jones, O. Abeyakoon and L. R. McNally, Development of multispectral optoacoustic tomography as a clinically translatable modality for cancer imaging, *Radiol.: Imaging Cancer*, 2020, **2**(6), e200066.
- 13 S. James, K. Neuhaus, M. Murphy and M. Leahy, Contrast agents for photoacoustic imaging: a review of stem cell tracking, *Stem Cell Res. Ther.*, 2021, **12**, 511.
- 14 V. Sabapathy, J. Mentam, P. M. Jacob and S. Kumar, Noninvasive optical imaging and *in vivo* cell tracking of indocyanine green labeled human stem cells transplanted at superficial or in-depth tissue of SCID mice, *Stem Cells Int.*, 2015, 606415.
- 15 M. Filippi, F. Garello, C. Pasquino, F. Arena, P. Giustetto, F. Antico and E. Terreno, Indocyanine green labeling for optical and photoacoustic imaging of mesenchymal stem cells after *in vivo* transplantation, *J. Biophotonics*, 2019, **12**(5), e201800035.
- 16 J. M. Yoo, C. Yun, N. Q. Bui, J. Oh and S. Y. Nam, Photoacoustic monitoring of the viability of mesenchymal stem cells labeled with indocyanine green, *IRBM*, 2019, **40**(1), 45–50.
- 17 A. De Gasperi, E. Mazza and M. Prosperi, Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?, *World J. Hepatol.*, 2016, **8**(7), 355–367.
- 18 J. Pan, H. Deng, S. Hu, C. Xia, Y. Chen, J. Wang and Y. Wang, Real-time surveillance of surgical margins *via* ICG-based near-infrared fluorescence imaging in patients with OSCC, *World J. Surg. Oncol.*, 2020, **18**, 96.
- 19 J. S. Díaz Tovar, G. Kassab, N. M. Inada, V. Salvador Bagnato and C. Kurachi, Photodegradation in the infrared region of indocyanine green in aqueous solution, 2019 *SBFoton*



- International Optics and Photonics Conference*, SBFoton IOPC, Sao Paulo, Brazil, 2019, pp. 1–5.
- 20 M. Green and P. Howes, Micellar compositions for use in biological applications, *US pat.* 9267951B2, 2016.
 - 21 T. Fedatto Abelha, C. A. Dreiss, M. A. Green and L. A. Dailey, Conjugated polymers as nanoparticle probes for fluorescence and photoacoustic imaging, *J. Mater. Chem. B*, 2020, **8**, 592.
 - 22 M. Zhao, E. Leggett, S. Bourke, S. Poursanidou, S. Carter-Searjeant, S. Po, M. Palma do Carmo, L. A. Dailey, P. Manning, S. G. Ryan, L. Urbano, M. Green and A. Rakovich, Theranostic NIR-active conjugated polymer nanoparticles, *ACS Nano*, 2021, **15**, 8790.
 - 23 P. Howes, M. Green, J. Levitt, K. Suhling and M. Hughes, Phospholipid encapsulated semiconducting polymer nanoparticles, their use in cell imaging and protein attachment, *J. Am. Chem. Soc.*, 2010, **132**, 3989.
 - 24 F. Amadeo, V. Hanson, P. Murray and A. Taylor, DEAE-Dextran enhances the lentiviral transduction of primary human mesenchymal stromal cells from all major tissue sources without affecting their proliferation and phenotype, *Mol. Biotechnol.*, 2023, **65**(4), 544–555.
 - 25 Participation E. Animals (Scientific Procedures) Act 1986, Statute Law Database; [cited 2022 Jan 30], available from: <https://www.legislation.gov.uk/ukpga/1986/14/contents>.
 - 26 Y.-Y. Liua, Q. Chang, Z.-X. Sun, J. Liu, X. Deng, Y. Liu, A. Cao and H. Wang, Fate of CdSe/ZnS quantum dots in cells: Endocytosis, translocation and exocytosis, *Colloids Surf. B*, 2021, **208**, 112140.
 - 27 A. Taylor, A. Herrmann, D. Moss, V. Sée, K. Davies, S. R. Williams and P. Murray, Assessing the efficacy of nano- and micro-sized magnetic particles as contrast agents for MRI cell tracking, *PLoS One*, 2014, **9**(6), e100259.
 - 28 L. P. Fernando, P. K. Kandel, J. Yu, J. McNeill, P. C. Ackroyd and K. A. Christensen, Mechanism of cellular uptake of highly fluorescent conjugated polymer nanoparticles, *Biomacromolecules*, 2010, **11**(10), 2675–2682.
 - 29 N. Onda, R. Mizutani-Morita, S. Yamashita, R. Nagahara, S. Matsumoto, T. Yoshida and M. Shibutani, Fluorescence contrast-enhanced proliferative lesion imaging by enema administration of indocyanine green in a rat model of colon carcinogenesis, *Oncotarget*, 2017, **8**, 90278–90290.
 - 30 N. Onda, M. Kimura, T. Yoshida and M. Shibutani, Preferential tumor cellular uptake and retention of indocyanine green for *in vivo* tumor imaging, *Int. J. Cancer*, 2016, **139**, 673–682.
 - 31 T. Desmettre, J. M. Devoisselle and S. Mordon, Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography, *Surv. Ophthalmol.*, 2000, **45**(1), 15–27.
 - 32 J. Sharkey, L. Ressel, N. Brilliant, L. Scarfe, B. Wilm, B. K. Park and P. Murray, A noninvasive imaging toolbox indicates limited therapeutic potential of conditionally activated macrophages in a mouse model of multiple organ dysfunction, *Stem Cells Int.*, 2019, 7386954.
 - 33 M. A. Saleemi, M. H. Fouladi, P. V. C. Yong, K. Chinna, N. K. Palanisamy and E. H. Wong, Toxicity of carbon nanotubes: molecular mechanisms, signalling cascades, and remedies in biomedical applications, *Chem. Res. Toxicol.*, 2021, **34**(1), 24–46.
 - 34 A. Hernandez Pichardo, J. Littlewood, A. Taylor, B. Wilm, R. Lévy and P. Murray, Multispectral optoacoustic tomography is more sensitive than micro-computed tomography for tracking gold nanorod labelled mesenchymal stromal cells, *J. Biophotonics*, 2023, **11**, e202300109, DOI: [10.1002/jbio.202300109](https://doi.org/10.1002/jbio.202300109).
 - 35 J. Weber, P. C. Beard and S. E. Bohndiek, Contrast agents for molecular photoacoustic imaging, *Nat. Methods*, 2016, **13**(8), 639–650.

